NCT05663268View on ClinicalTrials.gov

Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis Suppurativa

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

March 30, 2023

Study Completion Date

September 30, 2023

Conditions
Hidradenitis Suppurativa
Interventions
BIOLOGICAL

Infliximab-dyyb biosimilar

Remsima for subcutaneous injection is a biosimilar monoclonal antibody of infliximab-dyyb that inhibits the activity of tumour necrosis factor (TNF)-alpha.

Trial Locations (1)

54000

Services Institute of Medical Sciences, Lahore

All Listed Sponsors
lead

Services Institute of Medical Sciences, Pakistan

OTHER_GOV